- AstraZeneca released updated details of its latest clinical trial results, after a U.S. safety board raised concerns that data released earlier in the week may have been “outdated.”
- Results published on March 25 were based on an analysis of data from the phase 3 clinical trial, which included more than 32,000 participants in the United States, Chile, and Peru.
- The company plans to request emergency approval of its COVID-19 vaccine in the coming weeks.
Vaccine maker AstraZeneca released updated details about how well its coronavirus vaccine works. The vaccine showed 76 percent efficacy against symptomatic coronavirus infection, the company said Wednesday in a statement.
The vaccine also showed 100 percent efficacy against severe or critical disease or hospitalization, and 85 percent overall efficacy in people 65 years or older, the company said.
The results were similar to what the company announced in a statement Monday.
As before, the results were announced in a news release, so details are sparse. They have also not been peer-reviewed or reviewed by Food and Drug Administration scientists.
“The primary analysis is consistent with our previously released interim analysis, and confirms that our COVID-19 vaccine is highly effective in adults, including those aged 65 years and over,” Mene Pangalos, executive vice president for biopharmaceuticals research for the company, said in the news release.
The company said it plans to submit an application for emergency approval to the FDA in the coming weeks.
FDA scientists will review the company’s data in depth and present its analysis to the
The company also plans to submit its full analysis to a peer-reviewed journal for publication.
Source: healthline